Alvotech re­ceives an­oth­er CRL from the FDA for Hu­mi­ra biosim­i­lar can­di­date

Biosim­i­lar de­vel­op­er Alvotech has once again been hand­ed a com­plete re­sponse let­ter from the FDA.

On Wednes­day, the com­pa­ny an­nounced that it re­ceived a re­jec­tion for the sec­ond BLA for AVT02, a high-con­cen­tra­tion biosim­i­lar can­di­date for Hu­mi­ra. Ac­cord­ing to Alvotech’s re­lease, the most re­cent ap­pli­ca­tion had more da­ta and in­for­ma­tion at­tached. But the CRL not­ed the agency found “cer­tain de­fi­cien­cies” in its rein­spec­tion of Alvotech’s fa­cil­i­ty in Reyk­javik, Ice­land, in March. These de­fi­cien­cies, the CRL stat­ed, must be ad­dressed be­fore an ap­proval can be grant­ed. Alvotech not­ed that no oth­er is­sues in the ap­pli­ca­tion were not­ed by the FDA.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER